Ranbaxy got USFDA nod for Risperdal
The country's largest drugmaker Ranbaxy Laboratories received the US food and drug administration (USFDA) nod to sell generic version of Risperdal used in the treatment of schizophrenia in the US.
By PTI |
NEW DELHI: The country's largest drugmaker Ranbaxy Laboratories received the US food and drug administration (USFDA) nod to sell generic version of Risperdal used in the treatment of schizophrenia in the US.
As per the information on the regulator's website, the company has got a go ahead from USFDA to market and manufacture Risperidone in multiple strengths of 0.25 mg to 4 mg.
The drug Risperidone is used to is used to treat the symptoms of schizophrenia. It is also to treat behaviour problems such as aggression and self-injury and sudden mood changes in teenagers and children with autism.
As per the information on the regulator's website, the company has got a go ahead from USFDA to market and manufacture Risperidone in multiple strengths of 0.25 mg to 4 mg.
The drug Risperidone is used to is used to treat the symptoms of schizophrenia. It is also to treat behaviour problems such as aggression and self-injury and sudden mood changes in teenagers and children with autism.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
